Healthpoint Biotherapeutics, a developer of products for tissue repair and healing, has acquired Systagenix's Regranex Gel, along with its corresponding intellectual property.

Regranex Gel (0.01% Becaplermin), a recombinant human platelet-derived growth factor (rhPDGF), is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond, and have adequate blood supply.

The product has biological activity similar to that of endogenous platelet-derived growth factor, which includes promoting the chemotactic recruitment and proliferation of cells involved in wound repair and enhancing the formation of granulation tissue.

Regranex Gel, in conjunction with good ulcer care, demonstrated a statistically significant increase in the incidence of complete healing (defined as complete ulcer closure) versus placebo gel.

Healthpoint Biotherapeutics’ other products include Collagenase SANTYL Ointment, OASIS Wound Matrix, OASIS Ultra Tri-Layer Matrix and Regranex Gel.